September 10, 2025Frontiers in OncologyOpen Access

Liquid clues: tracking early-stage breast cancer with ctDNA - a mini review

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This mini review discusses ctDNA's role in early breast cancer management, highlighting detection and response assessment.

Circulating tumor DNA (ctDNA) may improve early detection in patients with non-metastatic breast cancer, enhancing clinical outcomes.
Assay sensitivity advancements can facilitate monitoring treatment responses and residual disease, providing better patient care.
Key therapeutic intervention trials integrating ctDNA into management strategies are essential for improving clinical practice in early breast cancer.
The potential of ctDNA lies in its application for personalized medicine in early-stage breast cancer, with significant future implications.

Easaw et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark